In line with our estimates and the consensus, Jupiter Lifeline Hospital reported healthy Q1 figures, with revenue/EBITDA up 21%/22% y/y. PAT, however, dipped a tad, 1% y/y due to higher interest cost and depreciation charges.
Strong beat on all fronts, with broad-based growth. Sharper RAC growth vs brands indicate continued shift to outsourcing though high channel inventory (~2.2m-2.5m vs. 1m-1.2m norm) could dampen near-term momentum.
Nilkamal’s Q1 revenue surged 18.9% y/y to Rs8.8bn. Gross profit was up 15.5% y/y to Rs3.7bn. Business restructuring and front-loading of costs w.r.t the Hosur, TN plant restricted EBITDA to Rs580m, up 2.9% y/y.
Greenply’s Q1 revenue grew 2.9%y/y to Rs6bn. Easing input costs pushed the gross margin up 205bps y/y to 42.8%. Higher employee and other expenses restricted the EBITDA margin improvement to 34bps y/y, to 10.3%. Adj. PAT fell 27.6% y/y to Rs240m.
Despite MOIL reporting its highest quarterly production of 0.502m tonnes (up 6.8% y/y) in Q1, sales were down 21.4% y/y to 0.356m tonnes. We believe, when Q1 crude steel production rose 10.4% y/y (40.3m tonnes), the early monsoon in May’25 cut MOIL’s offtake.
Driven by the initial consolidation of Heubach (for 28 days; y/y, q/q not comparable), which brought Rs5.25bn revenue and a 55.8% gross margin in Mar, Sudarshan Chemicals’ Q4 FY25 revenue was up 77% y/y to Rs13.5bn and adj. EBITDA, 24% y/y to Rs1.48bn.
Suraj’s Q1 bookings were soft, though collections increased. With unsold stocks of ~15,000 sq.ft. (~1x quarterly pre-sales), management has a pressing need to come up with significant launches in coming quarters, especially the expected impact launch of a commercial project in Mahim (of Rs12bn GDV) by Q2/Q3 FY26.